Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Medicine T-VISA-PEA15 capable of effectively and specifically killing breast cancer cells

A T-VISA-PEA15, breast cancer cell technology, applied in the field of medicine and biology, can solve the problems of no tissue specificity of the promoter, low promoter activity, and large toxic and side effects, and achieve no liver and kidney toxicity and high gene expression. , the effect of low toxicity

Active Publication Date: 2012-08-15
SUN YAT SEN UNIV CANCER CENT
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The cytomegalovirus promoter (CMV) widely used in tumor gene therapy is currently the most active promoter, but the promoter has no tissue specificity and highly expresses the target gene in normal cells. The currently developed clinical trial product Although it has a certain curative effect, it cannot be approved by SFDA (China Food and Drug Administration) and U.S. FDA (Food and Drug Administration) for clinical use due to its large toxicity and side effects.
Some researchers also used tumor-specific promoters instead of CMV for gene therapy research, and found that the toxic and side effects of gene therapy were greatly reduced, but due to the low activity of the promoter, its curative effect became very limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine T-VISA-PEA15 capable of effectively and specifically killing breast cancer cells
  • Medicine T-VISA-PEA15 capable of effectively and specifically killing breast cancer cells
  • Medicine T-VISA-PEA15 capable of effectively and specifically killing breast cancer cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1: Construction of T-VISA-PEA15 therapeutic vector

[0019] (1) pCRII-TOPO-hTERT plasmid clone

[0020] 1. Extract DNA from breast cancer MCF-7 cells (purchased from ATCC, USA) by conventional methods.

[0021] 2. Using the DNA as a template, design PCR primers for amplifying hTERT, hTERT PCR upstream (Forward) and downstream (Reverse) primers:

[0022] Forward: 5′-ata tct aga ggc ccc tcc ctc ggg tta ccc cac agc-3′(XbaI)

[0023] Reverse: 5′-ata gat ctt atg cgg ccg ccc acg tgc gca gca gga cgc agc gc-3′.

[0024] 3. Using breast cancer MCF-7 cell DNA as template, hTERT PCR primers (Forward: 5′-ata tct aga ggc ccc tcc ctc ggg tta ccc cac agc-3′; Reverse: 5′-ata gat ctt atg cgg ccg ccc acg tgc gca gca gga cgc agc gc-3'), Pfu DNA polymerase, dNTP and PCR reaction solution, amplify to obtain hTERT promoter (-416 to +1) product, the sequence of which is shown in SEQ ID NO.2. Its PCR reaction system: 10×PCR buffer 5μl, upstream (Forward) and downstream (Reverse) pr...

Embodiment 2

[0080] Example 2: Preparation of liposomes:

[0081] The lipids were removed from the refrigerator (DOTAP at -20°C, cholesterol at -4°C) and returned to room temperature. Heat the two rotary evaporators in a water bath to 30 °C and 50 °C, respectively. Weigh 68.75 mg of cholesterol into a 1000 ml round bottom flask. To a round bottom flask was added 100 mg of DOTAP and 25 mg of Chloroform. Swirl the flask to mix well. Rotate the round-bottomed flask in a water bath at 30°C for 2 min to make it evenly mixed and form a thin film on the wall of the flask. Turn on the vacuum aspirator for 30 min at 30°C. Add 8.9 ml of pre-warmed 5% glucose solution to dissolve the dried film, and spin rapidly at 105 rpm for 45 min at 50°C. Then reduce the temperature to 35°C and rotate for 10min. Cover the flask with plastic wrap (or paraffin) and leave at room temperature overnight, protected from light. Measure the volume and add double distilled water to 8.9 ml. The flask was sonicated ...

Embodiment 3

[0082] Example 3: Preparation of T-VISA-PEA15 liposomes

[0083] The T-VISA-PEA15 therapeutic vehicle was dissolved in a 5% glucose solution to a final concentration of 1 ug / ul, while the storage concentration (20 mM) of the liposome of Example 2 was diluted with a 5% glucose solution to a working concentration (8 mM) . 1 μg DNA / ul of T-VISA-PEA15 therapeutic vehicle was slowly added to 8mM liposome (therapeutic vehicle: liposome = 20ug: 50ul), and allowed to stand at room temperature for 20 minutes to react to form T-VISA-PEA15 lipid plastid.

[0084] Then, the quality control such as verification, biological property testing and endotoxin, etc., are aseptically packaged. Finished product inspection, packaging, and storage at 4-8 °C; put it at room temperature for 20 minutes before use, it can be used directly for in vitro research, or in vivo research, or it can be diluted with 5% glucose solution before use.

[0085] 2. Effect experiment:

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses a medicine T-VISA-PEA15 capable of effectively and specifically killing breast cancer cells. The sequence of a T-VISA-PEA15 therapy vector capable of effectively and specifically killing the breast cancer cells is shown as SEQ ID NO.1. A liposome of the medicine T-VISA-PEA15 liposome capable of effectively and specifically killing the breast cancer cells comprises a liposome and the T-VISA-PEA15 therapy vector coated by the liposome, wherein the nucleotide sequence of the T-VISA-PEA15 therapy vector is shown as SEQ ID NO.1. After being coated by the liposome and transferred, the T-VISA-PEA15 therapy vector is enriched on the breast cancer part, so as to effectively target the breast cancer ERK (extracellular signal-regulated kinase) target point and inhibit the breast cancer ERK target point from entering the nucleus, thereby promoting the apoptosis of tumor cells, but not killing the normal cells. The medicine T-VISA-PEA15 can be applied to a whole body and has of the advantages of high gene expression amount, long gene expression time, high gene expression efficiency, definite efficacy, low toxicity and side effect, no toxicity to liver and kidneys and wide prospect in the treatment of the breast cancer.

Description

Technical field: [0001] The invention belongs to the field of medical biology, and in particular relates to a drug T-VISA-PEA15 which can kill breast cancer cells with high efficiency and high specificity. Background technique: [0002] Breast cancer is the most common malignant tumor in women, and its incidence is increasing year by year, which seriously endangers the physical and mental health of human beings. Intermediate-advanced and recurrent and metastatic breast cancer patients are prone to tolerance to existing radiotherapy and chemotherapy, and their prognosis is poor. Therefore, there is an urgent need to develop a new drug with high-efficiency targeted killing of breast cancer. [0003] Gene therapy has a history of development for more than 20 years, and it is hoped that it can become an effective alternative to surgery, radiotherapy and chemotherapy and targeted therapy. At present, the cytomegalovirus promoter (CMV) widely used in tumor gene therapy is the mo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/63A61K48/00A61K9/127A61P35/00
Inventor 谢小明谢新华李来胜郭姣丽伍民庆孔亚楠韦尉东肖祥胜唐军王曦刘鹏
Owner SUN YAT SEN UNIV CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com